The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

Maintenance treatment refers to drugs that are given to try to slow or prevent or delay the cancer's return after it has responded to chemotherapy. Currently the PARP inhibitors (one of which is rucaparib) are the only type of targeted treatment licensed for maintenance use in ovarian cancer in the UK. Nivolumab is a different type of targeted t…